ATE235240T1 - Wässriges verfahren zur herstellung fester paroxetin-dispersionen - Google Patents

Wässriges verfahren zur herstellung fester paroxetin-dispersionen

Info

Publication number
ATE235240T1
ATE235240T1 AT99920358T AT99920358T ATE235240T1 AT E235240 T1 ATE235240 T1 AT E235240T1 AT 99920358 T AT99920358 T AT 99920358T AT 99920358 T AT99920358 T AT 99920358T AT E235240 T1 ATE235240 T1 AT E235240T1
Authority
AT
Austria
Prior art keywords
paroxetine
dispersions
amorphous
producing solid
aqueous process
Prior art date
Application number
AT99920358T
Other languages
English (en)
Inventor
William A Ii Hein
Sou-Chan Chang
Huai-Hung D Kao
Original Assignee
Endo Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Pharmaceuticals Inc filed Critical Endo Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE235240T1 publication Critical patent/ATE235240T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT99920358T 1998-05-07 1999-05-05 Wässriges verfahren zur herstellung fester paroxetin-dispersionen ATE235240T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/074,355 US6168805B1 (en) 1998-05-07 1998-05-07 Aqueous process for manufacturing paroxetine solid dispersions
PCT/US1999/009835 WO1999056751A1 (en) 1998-05-07 1999-05-05 Aqueous process for manufacturing paroxetine solid dispersions

Publications (1)

Publication Number Publication Date
ATE235240T1 true ATE235240T1 (de) 2003-04-15

Family

ID=22119113

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99920358T ATE235240T1 (de) 1998-05-07 1999-05-05 Wässriges verfahren zur herstellung fester paroxetin-dispersionen

Country Status (14)

Country Link
US (1) US6168805B1 (de)
EP (1) EP1075263B1 (de)
JP (1) JP2002513760A (de)
KR (1) KR20010043418A (de)
CN (1) CN1115149C (de)
AT (1) ATE235240T1 (de)
AU (1) AU3787699A (de)
CA (1) CA2331288C (de)
DE (1) DE69906269T2 (de)
ES (1) ES2196803T3 (de)
HK (1) HK1038699B (de)
MX (1) MXPA00010928A (de)
WO (1) WO1999056751A1 (de)
ZA (1) ZA993081B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
US6699882B2 (en) 1998-03-24 2004-03-02 Smithkline Beecham P.L.C. Paroxetine compositions
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
DE10000792A1 (de) * 2000-01-11 2001-07-19 Bernhard C Lippold Formulierungen von Wirkstoffen in Form einer festen Dispersion
GB0003232D0 (en) * 2000-02-11 2000-04-05 Smithkline Beecham Plc Novel composition
US6660298B1 (en) * 2000-07-27 2003-12-09 Pentech Pharmaceuticals, Inc. Paroxetine tablets and capsules
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
US20030032809A1 (en) * 2001-04-25 2003-02-13 Subhash P. Upadhyaya Optimized procedures for the manufacture of paroxetine salts
AU2002314968B2 (en) * 2001-06-08 2006-12-07 Endo Pharmaceuticals, Inc. Controlled release dosage forms using acrylic polymer, and process for making the same
EP1412350A1 (de) * 2001-08-02 2004-04-28 Spurcourt Limited Paroxetin isethionatsalz, herstellungsverfahren und anwendung bei der behandlung von depression
GB0119467D0 (en) * 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
IL162666A0 (en) * 2001-12-28 2005-11-20 Teva Pharma A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
WO2005107716A1 (en) * 2004-03-25 2005-11-17 Cadila Healthcare Limited Controlled release paroxetine-containing tablets based on a core and a coating
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
WO2007015270A2 (en) * 2005-08-02 2007-02-08 Lupin Limited Novel controlled release compositions of selective serotonin reuptake inhibitors
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CA2629514A1 (en) * 2005-11-14 2007-05-24 Auspex Pharmaceuticals, Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
CA2670113A1 (en) * 2006-12-01 2008-06-05 Basf Se Production of solid solutions of pesticides by short-term superheating and rapid drying
NZ585219A (en) * 2007-11-09 2012-11-30 Intervet Int Bv Fast release solid formulation, preparation and use thereof
EP2214679B1 (de) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Kortikosteroidzusammensetzungen
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
US20110097401A1 (en) 2009-06-12 2011-04-28 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
CN107802603B (zh) * 2017-12-14 2021-08-20 乐普制药科技有限公司 一种纳普醚醇分散体及其制备方法
CN110037995B (zh) * 2019-04-17 2021-07-06 石家庄龙泽制药股份有限公司 一种稳定的盐酸帕罗西汀片剂及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
CA2206592A1 (en) 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
ID23250A (id) 1997-01-15 2000-03-30 Smithkline Beecham Plc Komposisi paroksetin
US5955475A (en) 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions

Also Published As

Publication number Publication date
CN1115149C (zh) 2003-07-23
HK1038699B (zh) 2003-12-12
EP1075263B1 (de) 2003-03-26
EP1075263A1 (de) 2001-02-14
DE69906269T2 (de) 2004-01-29
ES2196803T3 (es) 2003-12-16
AU3787699A (en) 1999-11-23
CN1304308A (zh) 2001-07-18
WO1999056751A1 (en) 1999-11-11
HK1038699A1 (en) 2002-03-28
CA2331288C (en) 2007-01-23
KR20010043418A (ko) 2001-05-25
DE69906269D1 (de) 2003-04-30
JP2002513760A (ja) 2002-05-14
CA2331288A1 (en) 1999-11-11
ZA993081B (en) 1999-11-05
MXPA00010928A (es) 2005-06-06
US6168805B1 (en) 2001-01-02

Similar Documents

Publication Publication Date Title
DE69906269D1 (de) Wässriges verfahren zur herstellung fester paroxetin-dispersionen
NZ527585A (en) Tablets quickly disintegrated in oral cavity
WO2002069888A3 (en) Serotonin reuptake inhibitor formulations
DE60143765D1 (de) Antibiotische/analgetische formulierung und verfahren zur herstellung dieser formulierung
BR0008015A (pt) Uso de um composto, composto, composições farmacêuticas, e, processo para preparar um composto
BR9814729A (pt) Método e composição de uma preparação oral de itraconazol
ATE386725T1 (de) Heterocyclylverbindungen
CA2303498A1 (en) Dioxocyclopentyl hydroxamic acids
JP2005509052A5 (de)
BR0011831A (pt) Compostos, processo para preparar os mesmos, composições farmacêuticas, e, uso dos compostos
EP0992509A3 (de) Neue Makrolidderivate
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
ATE369840T1 (de) Orale zusammensetzungen von itraconazol und verfahren zu herstellung derselbigen
CA2429639A1 (en) Stable azithromycin monohydrate
CA2494601A1 (en) N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
KR880002541A (ko) α-인터페론의 적용 제형
DE60119905D1 (de) Verfahren zur herstellung fester dispersionen
ATE444739T1 (de) Polymerzusammensetzung sowie diese enthaltende darreichungsformen
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
DE50006842D1 (de) 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung
BR0112122A (pt) Composto de rutênio (ii) , uso de um composto, composição farmacêutica, método para tratar e/ou prevenir o câncer, e, processo para preparar um composto
ATE528301T1 (de) Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
AU2003233064A1 (en) Process for the preparation of the amorphous form of atorvastatin calcium salt
SE0001916D0 (sv) Novel formulation
AU2566101A (en) Compounds and methods for the treatment of pain

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties